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Objectives This study sought to analyze whether cardiovascular magnetic resonance (CMR) can detect and quantify myocar-
dial damage in the early stages of cardiomyopathy in muscular dystrophies (MD).
Background Muscular dystrophy is a genetic disease that involves skeletal and cardiac tissues of humans. Cardiomyopathy is
common, and death secondary to cardiac or respiratory diseases occurs early in life. Cardiovascular magnetic
resonance is a reliable method for assessing global and regional cardiac function, allowing also for the detection
of myocardial fibrosis (MF).
Methods Ten patients with Duchenne or Becker dystrophies were studied by CMR. Physical examination, Chagas disease
serological tests, electrocardiogram, chest radiograph, total creatine kinase, and Doppler echocardiogram were
also obtained in all patients.
Results Patients with MF had a lower ejection fraction than those without. Myocardial fibrosis (midwall and/or sub-
epicardial) was observed in 7 of the 10 patients, and the lateral wall was the most commonly involved segment.
There was moderate correlation between segmental MF and dysfunction.
Conclusions Cardiovascular magnetic resonance can identify MF and may be useful for detecting the early stages of cardio-
myopathy in MD. Future work will be needed to evaluate whether CMR can influence cardiomyopathy and
outcomes. (J Am Coll Cardiol 2007;49:1874–9) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.078e
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guscular dystrophy (MD) is a genetically determined group
f diseases with progressive degeneration of skeletal muscle.
hese diseases can be classified based on the pattern of
nheritance or on the muscle protein abnormality. The most
ommon X-linked MD is dystrophinopathy (1) caused by
he dystrophin gene (Xp21) mutation. Dystrophin is a
arcolemmal protein of skeletal and cardiac muscle cells
hat triggers complex molecular and biological events (2).
he most common forms of MD are Duchenne (1:3,000
en) and Becker (1:30,000 men) diseases, characterized
y absence and reduced or abnormal dystrophin, respec-
ively (3,4).
Death secondary to cardiac or respiratory causes typically
ccurs in the second to third decade in Duchenne and in the
ourth to fifth decade in Becker MD (3,4). In MD autopsy,
rom the *Axial Centro de Imagem, Belo Horizonte, and †Federal University of
inas Gerais Medical School, Minas Gerais, Brazil; and the ‡Human Genome
esearch Center, Biosciences Institute, University of São Paulo, and §Heart Institute
InCor) University of São Paulo Medical School, São Paulo, Brazil.fi
Manuscript received May 22, 2006; revised manuscript received September 21,
006, accepted October 16, 2006.nd-stage cardiac disease is characterized by alternating areas of
yocyte hypertrophy, atrophy, and fibrosis (5,6). Clinical
tudies of cardiomyopathy show that the heart disease
rocess is underway long before symptoms appear (7,8).
Cardiovascular magnetic resonance (CMR) is a precise and
eliable method for assessing global and regional cardiac
unction (9,10). Myocardial delayed enhancement (MDE) is
he best noninvasive method for evaluating myocardial fibrosis
MF) caused by ischemic (10,11) or nonischemic disease
12,13). We hypothesized that MDE can detect and quantify
yocardial damage caused by MD at early stages of disease.
ethods
e evaluated 10 patients with MD (8 Duchenne, 2 Becker) 7
o 18 years old. The dystrophinopathy was established by: 1)
NA analysis of the dystrophin gene (multiplex polymerase
hain reaction), and 2) dystrophin immunohistochemical anal-
sis in muscle tissue. In all patients, DNA analysis was
erformed. Three patients showed deletions in the dystrophin
ene, and 4 others had an absence of dystrophin in muscle
bers by biopsy (Table 1). Three patients had no deletions and
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May 8, 2007:1874–9 Dystrophy Cardiomyopathy by CMRpositive familiar history (Table 1). Two patients were
iblings, and presented proximal muscle weakness, hypore-
exia, calf hypertrophy, and onset of symptoms around 10
ears old, suggesting Becker MD. One had a classic Duchenne
henotype, an affected brother and a carrier mother with
ncreased serum creatine kinase (CK) level. Thus, these 3
atients had a diagnosis based on age of weakness onset, high
K levels, and an X-linked inheritance pattern.
All patients underwent cardiologic and neurologic evalu-
tion in the outpatient clinic of the Federal University of
inas Gerais, with routine physical examination, electro-
ardiography, chest radiograph, Doppler echocardiogram,
nd serum CK levels (Table 1).
Informed consent from patients or their legal represen-
atives preceded CMR evaluation and Chagas disease sero-
ogical test. Clinical characteristics are shown in Table 2.
MRmethods. The CMR examination was performed on
.5-T GE Signa LX System (GE Medical Systems,
akeusha, Wisconsin). Breath-hold left ventricular (LV)
hort-axis and long-axis images were obtained by 2 pulse
equences, at the same locations, allowing precise compar-
sons between LV function (gradient-echo sequence,
teady-state free precession) and myocardial structure
inversion-recovery prepared gradient-echo sequence, 10 to
0 min after intravenous bolus of 0.2-mmol/kg gadolinium-
ased contrast), acquired with the following parameters,
espectively: repetition time 3.9/7.1 ms, echo time 1.7/3.1
s, flip angle 45°/20°, cardiac phases 20/1, views per
egment 8/16 to 32, matrix 256  128/256  192, slice
hickness 8/8 mm, gap between slices 2/2 mm and field-of-
iew 32 to 38/32 to 38 cm, inversion time none/150 to 250
s, receiver bandwidth 125/31.25 kHz, number of excita-
ions 1/1, acquisition every other heartbeat for MDE.
ata analysis. End-systolic LV volume, end-diastolic LV
olume, and LV ejection fraction (LVEF) were measured
sing ReportCard 2.0 software (GE Medical Systems),
pplying the Simpson method. On the MDE short-axis
mages, we evaluated the number of LV segments with MF
sing a standard LV 17-segment model. Two independent
uscular Dystrophy Diagnosis and Treatment
Table 1 Muscular Dystrophy Diagnosis and Treatment
Patient # Age (yrs) Diagnosis DNA Deletion Muscle Biopsy
1 8 DMD* No NA
2 18 DMD Yes† NA
3 15 DMD Yes† NA
4 11 DMD Yes‡ NA
5 10 DMB§ No NA
6 13 DMB§ No NA
7 7 DMD No 
8 10 DMD No 
9 15 DMD No 
10 11 DMD No 
Classical Duchenne phenotype, affected brother and carrier mother with increased CK level. †Ex
  absence of dystrophin; Abnl  abnormal; ACEI  use of angiotensin-converting enzyme inh
2 years); CMR  cardiovascular magnetic resonance; DMB  Becker muscular dystrophy; DMD  Du
chocardiography; MF  myocardial fibrosis; Nl  normal; steroids  use of glucocorticoids; X-ray  conbservers scored segmental MDE
ransmurality as the visual percent
rea enhanced (nontransmural
50%, or transmural 51%), and
other observers evaluated myo-
ardial function as normal, mild
ypokinesia, severe hypokinesia,
nd akinesia or dyskinesia. Pat-
erns of MDE were classified as
ubendocardial, midwall, subepi-
ardial, and transmural.
tatistical analysis. Data are
resented as mean  standard
eviation. Chi-square analysis
as used for comparison between
roportions. Student t test was
sed for comparison between
roups with and without MF. Simple linear regression was
sed to compare total CK levels with LVEF. The kappa test
as used for agreement between observers and MF versus
egmental dysfunction. The Kruskal-Wallis test was used to
ompare mean scores among different segments. A limita-
ion of the statistical analysis was the small sample size.
esults
ix of the 8 patients with Duchenne dystrophy were already
heelchair-bound. All patients were negative for Chagas
isease. Seven of 10 patients had MF (70%), 6 had
uchenne MD, and 1 had Becker MD (Fig. 1, Table 1).
nly 2 patients had an abnormal cardiac silhouette on chest
adiograph; both presented MDE. Among the 7 patients
ith any electrocardiographic abnormality, 5 had MF by
MR. Only 1 patient had a Q-wave suggesting MF.
lobal LV and right ventricular (RV) function. Reduced
VEF (55%) was found in 2 patients by echocardiogram
nd in 3 patients by CMR. Ventricular morphologic and
unctional characteristics are shown in Table 3. Patients
Abbreviations
and Acronyms
CK  creatine kinase
CMR  cardiovascular
magnetic resonance
LV  left ventricle/
ventricular
LVEF  left ventricular
ejection fraction
MD  muscular dystrophy
MDE  myocardial delayed
enhancement
MF  myocardial fibrosis
RV  right ventricle/
ventricular
F by CMR Echo X-Ray ECG CK Steroids ACEI
No Nl Nl Abnl 11,596 Yes No
Yes Nl Nl Abnl 1,810 No No
Yes Abnl Abnl Abnl 1,495 No Yes
Yes Nl Nl Abnl 1,988 Yes No
No Nl Nl Nl 19,700 No No
Yes Nl Nl Nl 9,908 No No
Yes Nl Nl Nl 6,248 Yes No
Yes Nl Nl Abnl 9,420 Yes No
Yes Abnl Abnl Abnl 6,348 Yes Yes
No Nl Nl Abnl 4,270 No No
, 49, and 50. ‡Exons 51 and 52. §Siblings.
CK  creatine phosphokinase (normal values 109 U/l for older and 225 U/l for younger than
chenne muscular dystrophy; DNA  deoxyribonucleic a
ventional chest radiograph.M
ons 48
ibitors;cid; ECG  electrocardiogram; Echo 
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Dystrophy Cardiomyopathy by CMR May 8, 2007:1874–9ith MF (Fig. 2) showed a significantly lower LVEF and
igher end-systolic volume index than those without
Fig. 3). No differences were found for RV volumes and
unction (Table 3).
There was a trend to higher levels of total CK in patients
ith more preserved LVEF (r 0.54, p 0.10). Moreover,
atients with fibrosis tended to have lower levels of CK than
hose without fibrosis (Table 3).
egmental LV function and MF. For 2 independent
bservers, segmental MF was present in 33 (19.4%) and 25
14.7%) segments. Regional dysfunction was present in 25
14.7%) and in 23 (13.5%) segments. There was good
nterobserver agreement when analyzing LV function
kappa 0.76, p  0.001) and segmental MF (kappa 0.75, p
0.001). Comparing 340 observations (2 observers com-
ined), we noted moderate agreement between segmental
Clinical Characteristics Comparison
Table 2 Clinical Characteristics Comparison
All
(n  10)
Male 10 (100%)
Age (yrs) 12.5  3.1
Weight (kg) 46.7  14.6
Height (cm) 150.4  11.4
Body surface area (m2) 1.4  0.2
Wheelchair-bound 6 (60.0%)
Duchenne 8 (80.0%)
Becker 2 (20.0%)
Abnormal electrocardiogram 5 (50.0%)
Abnormal radiograph 2 (20.0%)
MF  myocardial fibrosis.
Figure 1 Myocardial Fibrosis in Duchenne and Becker Muscula
Adjacent short-axis (SA) and long-axis (LA) views of 2 patients with muscular dystro
resonance (CMR) using myocardial delayed enhancement technique. Between arroF and dysfunction, kappa 0.41, p 0.001. Only 10.6% of
egments with normal function showed MF, and 43.8% of
he dysfunctional segments had no MF. Among 58 MF
bservations, 27 (56.2%) had abnormal contractility. The
greement between the segmental MF extent and the
egree of segmental dysfunction was fair (kappa 0.31, p 
.001). Additionally, there was no segmental dysfunction in
1 (53.5%) of 58 MF observations, particularly with non-
ransmural MF (26 of 42, 61.9%).
Atypical patterns of MDE occurred in 89% of segments
ith MF; MF was midwall in 57.8% and subepicardial in
1.1%. Segmental MF was unequally distributed, with
ateral segments being most commonly involved for both
bservers (Table 4), and with the highest score (more MF)
or the combined observers (p  0.003 by Kruskal-Wallis
est).
With MF
(n  7)
Without MF
(n  3) p Value
7 (100%) 3 (100%)
13.1  3.6 11.0  0.0 0.35
46.6  15.1 47.0  16.6 0.97
153.7  12.2 142.7  3.1 0.17
1.4  0.3 1.4  0.2 0.80
5 (71.4%) 1 (33.3%) 0.26
6 (85.7%) 2 (33.3%) 0.26
1 (14.3%) 1 (66.7%) 0.26
4 (57.1%) 1 (33.3%) 0.50
2 (28.6%) 0 0.47
trophy by CMR
op: Duchenne, bottom: Becker) by cardiovascular magnetic
regions of myocardial delayed enhancement indicating myocardial fibrosis.r Dys
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May 8, 2007:1874–9 Dystrophy Cardiomyopathy by CMReproducibility. In 2 patients, we repeated the CMR study
0 days after the first study. Segmental MF had the same
ocation (4 for each patient) and extent for both studies.
iscussion
ilated cardiomyopathy is an increasing cause of death in
atients with Duchenne and Becker MD because of a
ramatic improvement in respiratory care in the last 2
ecades. The time course for the development of cardiomy-
pathy has not been well characterized. Data from clinical
tudies suggest that heart disease is underway long before
ymptoms appear (7).
Cardiovascular Magnetic Resonance VentricularKinase Leve s in Muscular Dystrophy With and W
Table 3 Cardiovascular Magnetic ResonancKinase Levels in Muscular Dystroph
All
(n  10)
LV EF (%) 53.7 12.5
LV EDV (ml/m2) 68.1 17.6
LV ESV (ml/m2) 32.6 14.8
LV mass (g/m2) 106.8 34.6
LV EDD (cm) 4.7 0.7
LV ESD (cm) 3.4 0.8
LV ASWT (mm) 8.6 0.7
LV ILWT (mm) 8.5 1.1
RV EF (%) 54.8 10.3
RV EDV (ml/m2) 59.0 14.2
RV ESV (ml/m2) 26.6 9.0
Total creatine kinase* 7,278.3 5,644.6
*Normal levels 190 UI/l for men and 225 UI/l for children 12 ye
ASWT  anteroseptal wall thickness; EDD  end-diastolic diamet
diameter; ESV  end-systolic volume; ILWT  inferolateral wall thickn
Figure 2 Myocardial Fibrosis and Dysfunction in Muscular Dyst
A patient example with Duchenne muscular dystrophy showing lateral myocardial d
thickening between septal [black arrowheads] and lateral [white arrowheads] waWe used the ability of CMR to delineate RV and LV
orphology, function, and myocardial tissue characteristics
n patients with Duchenne and Becker MD. The presence
f MF was consistently shown by the MDE technique in
ur patients with MD.
The frequent finding of MF, even in patients with
reserved global LV and RV function, supports the current
elief that heart disease begins much earlier than the onset
f symptoms (7). Moreover, this observation suggests that
MR can be useful for the early detection of heart disease
ver and above the sole information on ventricular function
rovided by the conventional Doppler echocardiogram. We
tion and Creatineut Myocardial Fibrosis
tricular Function and Creatine
h and Without Myocardial Fibrosis
ith MF
n  7)
Without MF
(n  3) p Value
.3 11.0 66.1 0.6 0.02
.7 16.4 55.1 14.6 0.13
.5 13.5 18.7 5.4 0.04
.9 36.9 83.3 11.9 0.17
.8 0.7 4.3 0.3 0.28
.6 0.9 3.0 0.2 0.23
.6 0.5 8.7 1.2 0.86
.6 1.3 8.3 0.6 0.77
.8 9.3 61.7 10.9 0.18
.7 11.6 59.7 22.4 0.93
.6 9.5 21.8 6.5 0.30
.7 3,601.6 11,855.3 7,718.3 0.09
.
 end-diastolic volume; EF  ejection fraction; ESD  end-systolic
 left ventricular; MF  myocardial fibrosis; RV  right ventricular.
by Cardiovascular Magnetic Resonance
enhancement (MDE) and lateral akinesia (compare the wall
d global left ventricular dysfunction (left ventricular ejection fraction 41%).Funcitho
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Dystrophy Cardiomyopathy by CMR May 8, 2007:1874–9lso observed that even among patients with MF, the chest
adiograph and electrocardiogram were completely normal.
nother interesting observation is the detection of myocar-
ial injury at a very young age. We detected MF in 2 of 4
atients 10 years old with normal echocardiogram, a time
hen drug treatment is still not usually indicated (14).
Global LV dysfunction was associated with the presence
f MF, indicating an MF role in the development of
ardiomyopathy and heart failure in MD. Myocardial de-
ayed enhancement pattern preserving subendocardium and
ore frequently located in the LV lateral wall has been
bserved in other cardiomyopathies (12,13). The correlation
etween segments with MF and dysfunction reinforces the
athophysiological link. In this regard, the dystrophin gene
utation has been associated not only with X-linked dilated
ardiomyopathy, but also with sporadic dilated cardiomy-
pathy (15,16). Previous work has suggested that dystro-
hin gene exon 51 to 52 mutations protect against the
evelopment of dilated cardiomyopathy (17). We had 1 case
ith this specific mutation and 2 cases with the exon 48, 49,
Figure 3 Absence of Myocardial Fibrosis and Normal Function i
A patient with Duchenne muscular dystrophy showing no myocardial delayed enhan
Segmental LV MF Distribution
Table 4 Segmental LV MF Distribution
LV Wall
Observer 1
With MF Without MF
Lateral 19 (38.0) 31 (62.0)
Septal 6 (12.0) 44 (88.0)
Anterior 4 (10.0) 36 (90.0)
Inferior 4 (13.3) 26 (86.7)
Total 33 137Absolute frequencies (row percent). p  0.001 for both observers by chi-squa
Abbreviations as in Table 3.nd 50 mutations (Table 1). All 3 of these patients had MF
n CMR studies. Moreover, of 7 patients with MF, only 2
ad abnormal echocardiography. In light of our data, it is
ossible that patients with normal echocardiography might
lready have myocardial injury shown by CMR studies.
herefore, the use of CMR, leading to a more detailed
valuation of these patients, particularly the MF detection,
an be useful.
Standard heart failure management, although supported
y few data, has been used in this group of patients with
uboptimal results (18). Systemic glucocorticoid administra-
ion is becoming the standard treatment for skeletal muscle
isease, and it may be beneficial to cardiac function.
herefore, further studies are needed to investigate the
se of MF by CMR as a surrogate for the beginning of
edical therapy for heart failure, with potentially better
esults. Moreover, the early use of drugs, known to act on
he development of MF, such as aldosterone and
ngiotensin-converting enzyme inhibitors, also needs to
e investigated.
scular Dystrophy by Cardiovascular Magnetic Resonance
nt (MDE) and normal global and segmental left ventricular function.
Observer 2
TotalWith MF Without MF
16 (32.0) 54 (68.0) 50 (100)
5 (10.0) 45 (90.0) 50 (100)
2 (5.0) 38 (95.0) 40 (100)
2 (6.7) 28 (93.3) 30 (100)
25 145 170n Mu
cemere test.
CC
e
o
c
m
h
g
i
M
R
I
M
M
C
B
R
1
1
1
1
1
1
1
1
1
1879JACC Vol. 49, No. 18, 2007 Silva et al.
May 8, 2007:1874–9 Dystrophy Cardiomyopathy by CMRonclusions
ardiovascular magnetic resonance can detect MF in the
arly stage of cardiomyopathy in patients with MD, when
ther abnormalities cannot be recognized by a standard
ardiologic evaluation. Myocardial delayed enhancement
ay be useful to further monitor the effectiveness of medical
eart failure treatment and to evaluate new strategies tar-
eting the molecular etiology. Whether this approach will
nfluence the cardiomyopathy mortality in patients with
D requires further investigation.
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edicina da Universidade de São Paulo, Setor de Ressonância
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